An HSVtk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice

Cancer Gene Therapy

Volumn 4, Issue 4, 1997, Pages 246-252

  Bi, Wanli ^a   Kim, Young Gyu ^a   Feliciano, Estrella S ^a   Pavelic, Ljiljana ^a   Wilson, Keith M ^a   Pavelic, Zlatko P ^a   Stambrook, Peter J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Ganciclovir; Gene therapy; Head and neck tumors; Herpes thymidine kinase; Therapy

Indexed keywords

THYMIDINE KINASE;

ANIMAL; ARTICLE; CELL STRAIN 3T3; EXPERIMENTAL NEOPLASM; GENE THERAPY; GENE VECTOR; GENETICS; HEAD AND NECK TUMOR; HERPES SIMPLEX VIRUS; HUMAN; MOUSE; MOUSE MUTANT; NUDE MOUSE;

3T3 CELLS; ANIMALS; GENE THERAPY; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, NUDE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; SIMPLEXVIRUS; THYMIDINE KINASE;

EID: 0031179187     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Plautz GE, Yang ZY, Wu BY, Gao X, Huang L, Nabel GJ. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA. 1993;90:4645-4649.
2. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986;46: 5276-5281.
3. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector - producer cells for treatment of experimental brain tumors. Science. 1992;256:1550-1552.
4. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53: 5274-5283.
5. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Human Gene Ther. 1993;4:725-731.
6. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated mediated by connexins. Proc Natl Acad Sci USA. 1996;93:1831-1835.
7. Elshami AA, Saavedra A, Zhang H, et al. Gap junction play a role in the "bystander effect" of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 1996;3:85-92.
8. Shinoura N, Chen L, Wani MA, et al. Protein and messenger RNA expression of connexin43 in astrocytomas: implication in brain tumor gene therapy. J Neurosurg. 1996;84:839-846.
9. Miller AD, Buttimore C. Redesign of retroviral packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol. 1986;6:2895-2902.
10. Cepko C. Transduction of genes using retrovirus vectors. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K, eds. Current Protocols in Molecular Biology. New York: John Wiley & Sons, Inc.; 1993:unit 9.10-9.14.
11. Wu JK, Cano WG, Meylaerts SA, Qi P, Vrionis F, Cherington V. Bystander tumoricidal effect in the treatment of experimental brain tumors. Neurosurgery. 1994;35: 1094-1102.
12. Ram Z, Wallbridge S, Shawker T, Culver KW, Blaese RM, Oldfield EH. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg. 1994;81:256-260.
13. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann JL, Klatzmann D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA. 1993;90:7024-7028.
14. Tapscott SJ, Miller AD, Olson JM, Berger MS, Groudine M, Spence AM. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc Natl Acad Sci USA. 1994;91: 8185-8189.
15. Barba D, Hardin J, Sadelain M, Gage FH. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA. 1994;91:4348-4352.
16. Freeman SM, Ramesh R, Shastri M, Munshi A, Jensen AK, Marrogi AJ. The role of cytokines in mediating the bystander effect using HSVtk xenogeneic cells. Cancer Lett. 1995;92:167-174.
17. Ramesh R, Marrogi AJ, Munshi A, Abboud CN, Freeman SM. In vivo analysis of the "bystander effect": a cytokine cascade. Exp Hematol. 1996;24:829-838.
18. Chen SH, Chen XH, Wang Y, et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA. 1995;92:2577-2581.
19. Fidler IJ, Murray JL, Kleinerman ES. Systemic activation of macrophages by liposomes containing immunomodulators. In: Hellman S, DeVita VT, Jr, Rosenberg SA, eds. Biologic Therapy of Cancer: Principles and Practice. Philadelphia: J.B. Lippincott Co.; 1991:730-742.
20. Dziarski R. Opposing effects of xid and nu mutations on proliferative and polyclonal antibody and autoantibody responses to peptidoglycan, LPS, protein A and PWM. Immunology. 1984;53:563-574.
21. Sharp AK, Colston MJ. Elevated macrophage activity in nude mice. Exp Cell Biol. 1984;52:44-47.